Fascination About Rifampicin
DYRK1B kinase not too long ago emerged as a potential goal in cancer, metabolic syndrome, and nonalcoholic fatty liver disease, but The dearth of structural data hinders the design of selective DYRK1B inhibitors. Below, we provide a way for recombinant production, action assays, crystallization situations along with a superior resolution crystal st